Balb/c Mice as a Preclinical Model for Raltitrexed-induced Gastrointestinal Toxicity
Raltitrexed (RTX) is an antifolate thymidylate synthase (TS) inhibitor used for the treatment of advanced colorectal cancer. RTX induces proliferating tissue toxicities that are largely confined to the intestine, with diarrhea being a severe side effect in a small but significant minority of patient...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2000-01, Vol.6 (1), p.285-296 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Raltitrexed
(RTX) is an antifolate thymidylate synthase (TS) inhibitor used for the
treatment of advanced colorectal cancer. RTX induces proliferating
tissue toxicities that are largely confined to the intestine, with
diarrhea being a severe side effect in a small but significant minority
of patients. Similarly, weight loss and diarrhea were observed in
BALB/c mice, and a maximum tolerated dose (MTD) was determined as
approximately 5–10 mg/kg/day × 5 days. At an equivalent dose of
10 mg/kg/day × 5 days (d1–5), DBA2 mice lost considerably less
weight, leading to a higher MTD (>500 mg/kg/day × 5 days), and
there was no evidence of diarrhea. Histopathological consequences of
damage, such as changes in small intestinal crypt architecture and
villus atrophy induced by the 10-mg/kg/day dose, were greater and of
longer duration in BALB/c mice. A higher dose of RTX (100
mg/kg/day × 5) induced weight loss and histopathological damage
similar to that seen in BALB/c mice (10 mg/kg/day × 5) but was of
later onset, nadir, and recovery. Small changes to the colon were only
observed in BALB/c mice. Pretreatment levels of plasma thymidine,
deoxyuridine (∼1 μ m ), and folate (∼40 ng/ml) were
similar in both mouse strains. A single injection of radiolabeled RTX
(5 mg/kg/day) did not lead to any marked difference 24 h later in
the total drug concentration and distribution of polyglutamates
(comprising 70–80% of drug extracted) in the liver, kidney, and
intestinal epithelium (large and small intestine) between the two mouse
strains. Further studies used a RIA to measure RTX polyglutamate
formation in tissues at various times and drug doses. This led to the
conclusion that, although there was a higher accumulation of RTX in
BALB/c small intestinal epithelium (days 4–6), it may be an effect
secondary to another undetermined cause of increased drug sensitivity.
This model represents a vehicle by which the etiology and treatment of
severe clinical toxicity induced by RTX may be evaluated. |
---|---|
ISSN: | 1078-0432 1557-3265 |